Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890611 · ClinicalTrials.gov registry record · Phase 1
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
NCT06890611 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 125 participants.
The verdict
NCT06890611, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Interventions
- DRUG Tirzepatide
- DRUG Bimagrumab
- DRUG Bimagrumab + Tirzepatide Coformulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06890611
The ClinicalTrials.gov registry entry for NCT06890611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06890611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06890611 about?
NCT06890611 is a clinical study titled "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants". The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
What is the current status of trial NCT06890611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2025-03-25. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT06890611?
The interventions under investigation include: Tirzepatide (DRUG), Bimagrumab (DRUG), Bimagrumab + Tirzepatide Coformulation (DRUG).
Who is sponsoring clinical trial NCT06890611?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.